Cargando…
Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss
PURPOSE: To establish a high-risk prediction model for aromatase inhibitor-associated bone loss (AIBL) in patients with hormone receptor-positive breast cancer. METHODS: The study included breast cancer patients who received aromatase inhibitor (AI) treatment. Univariate analysis was performed to id...
Autores principales: | Chu, Meiling, Zhou, Yue, Yin, Yulian, Jin, Lan, Chen, Hongfeng, Meng, Tian, He, Binjun, Wu, Jingjing, Ye, Meina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174287/ https://www.ncbi.nlm.nih.gov/pubmed/37182163 http://dx.doi.org/10.3389/fonc.2023.1182792 |
Ejemplares similares
-
Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005) -
Association between endocrine therapy and cognitive decline in breast cancer based on propensity score matching
por: Yin, Yulian, et al.
Publicado: (2023) -
Aromatase Activity and Bone Loss in Men
por: Merlotti, Daniela, et al.
Publicado: (2011) -
Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
por: Huifang, Li, et al.
Publicado: (2022) -
Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)